Severe enterovirus infections in patients with immune-mediated inflammatory diseases receiving anti-CD20 monoclonal antibodies

Grégoire Martin de Frémont,Hélène Chabrolles,Audrey Mirand,Anne Sophie L'Honneur,Nicolas Mélé,Bertrand Dunogue,David Boutboul,Meryem Farhat,Eric Hachulla,Mouna Lazrek,Virginie Rieu,Alexis Mathian,Helene Chaussade,Aurelie Ruet,Sonia Burrel,Fabienne Coury-Lucas,Isabelle Schuffenecker,Adrien Lemaignen,Karl Stefic,Maelle le Besnerais,Marion Carrette,Luc Mouthon,Veronique Avettand-Fenoel,Benjamin Terrier,Jérome Hadjadj

DOI: https://doi.org/10.1136/rmdopen-2023-004036

2024-05-22

RMD Open

Abstract:Objective Patients with X linked agammaglobulinemia are susceptible to enterovirus (EV) infections. Similarly, severe EV infections have been described in patients with impaired B-cell response following treatment with anti-CD20 monoclonal antibodies (mAbs), mostly in those treated for haematological malignancies. We aimed to describe severe EV infections in patients receiving anti-CD20 mAbs for immune-mediated inflammatory diseases (IMIDs). Methods Patients were included following a screening of data collected through the routine surveillance of EV infections coordinated by the National Reference Center and a review of the literature. Additionally, neutralising antibodies were assessed in a patient with chronic EV-A71 meningoencephalitis. Results Nine original and 17 previously published cases were retrieved. Meningoencephalitis (n=21/26, 81%) associated with EV-positive cerebrospinal fluid (n=20/22, 91%) was the most common manifestation. The mortality rate was high (27%). EV was the only causal agents in all reported cases. Patients received multiple anti-CD20 mAbs infusions (median 8 (5–10)), resulting in complete B-cell depletion and moderate hypogammaglobulinemia (median 4.9 g/L (4.3–6.7)), and had limited concomitant immunosuppressive treatments. Finally, in a patient with EV-A71 meningoencephalitis, a lack of B-cell response to EV was shown. Conclusion EV infection should be evoked in patients with IMIDs presenting with atypical organ involvement, especially meningoencephalitis. Anti-CD20 mAbs may lead to impaired B-cell response against EV, although an underlying primary immunodeficiency should systematically be discussed.

rheumatology

What problem does this paper attempt to address?

The problem that this paper aims to solve is: **To explore the occurrence and clinical characteristics of severe enterovirus infections in patients with immune - mediated inflammatory diseases (IMIDs) receiving anti - CD20 monoclonal antibody treatment**.

Specifically, the paper focuses on the following points:

1. **Background issues**:
- It is known that patients with primary B - cell deficiencies such as X - linked agammaglobulinemia (XLA) are prone to severe enterovirus (EV) infections.
- Severe EV infections have also been reported in patients receiving anti - CD20 monoclonal antibodies (mAbs), especially those used to treat hematological malignancies. However, for patients with IMIDs treated with anti - CD20 mAbs, this risk has not been fully evaluated.

2. **Research objectives**:
- To describe severe EV infections occurring in IMIDs patients receiving anti - CD20 mAbs treatment.
- To understand the clinical manifestations, diagnostic delay, and treatment effects in these patients.
- To explore the impact of anti - CD20 mAbs on B - cell function, especially the neutralizing antibody response against EV.

3. **Key findings**:
- A total of 26 cases of severe EV infections were included in the study, of which 9 were newly reported cases and 17 were published cases.
- The most common clinical manifestation was meningoencephalitis, accompanied by EV - positive cerebrospinal fluid test results.
- High mortality (27%), especially in patients with cardiac involvement.
- Patients showed significant B - cell depletion and hypogammaglobulinemia after receiving multiple anti - CD20 mAbs infusions.
- A patient with AAV and treated with rituximab failed to produce an effective neutralizing antibody response in the case of chronic EV - A71 meningoencephalitis.

4. **Conclusions and implications**:
- EV infection should be considered when IMIDs patients have atypical organ involvement, especially meningoencephalitis.
- Anti - CD20 mAbs may weaken the B - cell immune response to EV, although the underlying primary immunodeficiency should also be systematically discussed.
- EV genome detection should be included in the initial microbiological screening to improve the chances of early diagnosis and timely treatment.

Through this study, the authors hope to raise clinicians' awareness of this potentially serious complication and provide guidance for future research and clinical practice.